Hikma Pharmaceuticals (LON:HIK) had its target price upped by Jefferies Group from GBX 1,045 ($14.06) to GBX 1,074 ($14.45) in a research note published on Monday. The brokerage currently has a hold rating on the stock.
HIK has been the topic of a number of other research reports. Barclays reduced their price target on Hikma Pharmaceuticals from GBX 2,200 ($29.61) to GBX 1,500 ($20.19) and set an overweight rating on the stock in a research note on Friday, August 25th. Stifel Nicolaus cut their target price on Hikma Pharmaceuticals from GBX 1,320 ($17.77) to GBX 1,000 ($13.46) and set a hold rating on the stock in a research report on Thursday, November 9th. Numis Securities raised Hikma Pharmaceuticals to a buy rating and set a GBX 1,300 ($17.50) price objective on the stock in a research report on Thursday, November 9th. Peel Hunt reiterated a hold rating and issued a GBX 1,390 ($18.71) price target on shares of Hikma Pharmaceuticals in a research note on Tuesday, October 31st. Finally, Goldman Sachs Group downgraded Hikma Pharmaceuticals to a neutral rating and decreased their target price for the company from GBX 2,600 ($34.99) to GBX 1,310 ($17.63) in a research note on Tuesday, August 22nd. One analyst has rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of Hold and an average target price of GBX 1,188.90 ($16.00).
Hikma Pharmaceuticals (HIK) traded up GBX 14.13 ($0.19) on Monday, hitting GBX 962 ($12.95). The company had a trading volume of 536,169 shares, compared to its average volume of 1,420,000. Hikma Pharmaceuticals has a 1-year low of GBX 906.50 ($12.20) and a 1-year high of GBX 2,346 ($31.57).
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Ratings for Hikma Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.